La maladie de Parkinson en France (serveur d'exploration) - Analysis (USA)

Index « Auteurs » - entrée « Penelope J. Hallett »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Penelope Hogarth < Penelope J. Hallett < Per Ivar Hoff  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 2.
Ident.Authors (with country if any)Title
000120 (2015) Gaynor A. Smith [États-Unis] ; Emily M. Rocha [États-Unis] ; Thomas Rooney [France] ; Pascal Barneoud [France] ; Jesse R. Mclean [États-Unis] ; Jonathan Beagan [États-Unis] ; Teresia Osborn [États-Unis] ; Madeleine Coimbra [France] ; Yongyi Luo [États-Unis] ; Penelope J. Hallett [États-Unis] ; Ole Isacson [États-Unis]A Nurr1 Agonist Causes Neuroprotection in a Parkinson’s Disease Lesion Model Primed with the Toll-Like Receptor 3 dsRNA Inflammatory Stimulant Poly(I:C)
000578 (2008) Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis]Striatal histone modifications in models of levodopa-induced dyskinesia

List of associated KwdEn.i

Nombre de
documents
Descripteur
1Abnormal movement
1Acute
1Animal model
1Animals
1Chronic
1Corpus striatum
1Development
1Disease Models, Animal
1Dopamine (biosynthesis)
1Dopaminergic Neurons (metabolism)
1Dopaminergic Neurons (pathology)
1Dyskinesia
1Encephalon
1Gene Expression
1Histone
1Imidazoles (administration & dosage)
1Inflammation (chemically induced)
1Inflammation (drug therapy)
1Inflammation (metabolism)
1Inflammation (pathology)
1Involuntary movement
1Levodopa
1Male
1Microglia (metabolism)
1Microglia (pathology)
1Modification
1Monkey
1Mouse
1Nerve Degeneration (drug therapy)
1Nerve Degeneration (pathology)
1Neuroprotection (drug effects)
1Nuclear Receptor Subfamily 4, Group A, Member 2 (agonists)
1Nuclear Receptor Subfamily 4, Group A, Member 2 (genetics)
1Oxidopamine (toxicity)
1Parkinson Disease, Secondary (drug therapy)
1Parkinson Disease, Secondary (metabolism)
1Parkinson Disease, Secondary (pathology)
1Parkinson disease
1Pars Compacta (drug effects)
1Pars Compacta (metabolism)
1Poly I-C (administration & dosage)
1Pyridines (administration & dosage)
1RNA, Double-Stranded
1Rats
1Toll-Like Receptor 3 (biosynthesis)
1Toll-Like Receptor 3 (genetics)
1Treatment

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/USA/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/USA/Analysis/Author.i -k "Penelope J. Hallett" 
HfdIndexSelect -h $EXPLOR_AREA/Data/USA/Analysis/Author.i  \
                -Sk "Penelope J. Hallett" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/USA/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    USA
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Penelope J. Hallett
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024